Searchable abstracts of presentations at key conferences in endocrinology

ea0097007 | Section | BES2023

Dose Reduction of Cyproterone Acetate in Trans Women and the Effect on Patient- reported Outcomes: Results from the ENIGI Study

Tim Flamant , Jeroen Vervalcke , Guy T'Sjoen

Context: Cyproterone acetate (CPA) is an androgen receptor blocker often used for testosterone suppression as a part of gender-affirming hormonal treatment (GAHT) in transgender women. In recent years, more concerns have been raised towards an increased risk of meningioma development, linked to CPA use in higher doses (25 mg or more per day).Objectives: To determine if lower doses of CPA are equally effective in maintain...

ea0097006 | Section | BES2023

Effects of Long-term Testosterone Treatment in Transgender People without Gender-Affirming Surgery: the ELANTES study

Karen Decaestecker , Jeroen Vervalcke , Visschere Pieter De , Steven Weyers , Guy T'Sjoen

Background: Since pelvic gender-affirming surgery (GAS) is no longer required for legal gender change, we expect a growing number of transgender men and gender nonbinary people who refrain from pelvic surgery. Little is known about the effects of long-term testosterone use on the reproductive organs. Polycystic ovaries and endometrial changes have been described in previous histology-based studies. Furthermore, cervical cancer screening (CCS) is still recommen...